A naukri.com initiative
Bioengineer
3d
60
Image Credit: Bioengineer
Investigational Cell Therapy Shows Early Promise as Potential Parkinson’s Treatment
- A stem cell-based therapy developed at MSK shows promise for Parkinson’s treatment, transplanting neurons derived from hESCs into patients' brains.
- Parkinson’s disease results from dopamine-producing neuron degeneration, causing motor function issues that lack effective treatment for halting disease progression.
- The therapy involves differentiating hESCs into dopamine neuron progenitors, creating an 'off-the-shelf' product for transplantation, showing successful engraftment in a phase 1 trial.
- Patients experienced stabilization or improvement in symptoms, with those receiving higher cell doses showing significant symptom reduction and increased 'ON' time.
- The trial’s success led to FDA approval for a larger phase 3 study to assess clinical benefit, durability, and dosing strategies of the therapy.
- Collaboration between Drs. Studer and Tabar at MSK led to the development of safety measures to minimize the risk of graft-induced dyskinesia.
- Advanced imaging techniques during cell delivery ensure precise implantation, setting new benchmarks for safety in regenerative therapies.
- The researchers suggest broader applications of this therapy beyond Parkinson’s disease, foreseeing potential benefits for other neurological conditions.
- Questions remain regarding long-term survival and functionality of transplanted neurons, driving ongoing monitoring and further study in phase 3.
- BlueRock Therapeutics sponsored the trials, showcasing successful collaboration between academia and industry in translating scientific discoveries to clinical applications.
- The therapy signifies a significant advancement in regenerative neurology, offering a promising shift from symptomatic control to restorative intervention in Parkinson’s disease management.
Read Full Article
3 Likes
For uninterrupted reading, download the app